HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AG NPP709

has anti-inflammatory, anti-tussiive, and expectorant activities; consists of Hedera helix and Coptis chinensis

Also Known As:

synatura

Networked: 3 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Plant Preparations: 622
    - Plant Extracts: 3916
      - AG NPP709: 3
Pharmaceutical Preparations
- Plant Extracts: 3916
  - AG NPP709: 3

Experts

1.	Lee, Eung Gu: 1 article (05/2020)
2.	Rhee, Chin Kook: 1 article (05/2020)
3.	Choi, Hye Duck: 1 article (11/2013)
4.	Han, Chang Kyun: 1 article (11/2013)
5.	Jung, Ji Won: 1 article (11/2013)
6.	Kang, Hee Eun: 1 article (11/2013)
7.	Kim, Ju Myung: 1 article (11/2013)
8.	Lee, Hye Suk: 1 article (11/2013)
9.	Shin, Young June: 1 article (11/2013)
10.	Yoon, Ji Na: 1 article (11/2013)

Related Diseases

1.	Chronic Bronchitis 05/01/2020 - "The aim of this study was to evaluate the efficacy of AG NPP709 in patients with chronic bronchitis type chronic obstructive pulmonary disease (COPD). " 05/01/2020 - "These results suggest that AG NPP709 is efficacious and safe in patients with chronic bronchitis type COPD." 05/01/2020 - "The clinical efficacy of AG NPP709 (Synatura®) in patients with chronic bronchitis type stable chronic obstructive pulmonary disease." 05/01/2020 - "AG NPP709 improved the quality of life, as represented by the CAT score, in patients with chronic bronchitis type COPD, and significantly reduced fibrinogen levels. "
2.	Chronic Obstructive Pulmonary Disease (COPD) 05/01/2020 - "The aim of this study was to evaluate the efficacy of AG NPP709 in patients with chronic bronchitis type chronic obstructive pulmonary disease (COPD). " 05/01/2020 - "These results suggest that AG NPP709 is efficacious and safe in patients with chronic bronchitis type COPD." 05/01/2020 - "The clinical efficacy of AG NPP709 (Synatura®) in patients with chronic bronchitis type stable chronic obstructive pulmonary disease." 05/01/2020 - "AG NPP709 improved the quality of life, as represented by the CAT score, in patients with chronic bronchitis type COPD, and significantly reduced fibrinogen levels. "
3.	Asthma (Bronchial Asthma) 09/19/2022 - "In this study, the therapeutic efficacy of Weissella cibaria strains CMU (Chonnam Medical University) and CMS (Chonnam Medical School) 1, together with the drug Synatura, an anti-tussive expectorant, was investigated in a murine asthma model exacerbated by DEPM. "
4.	Infections 05/01/2020 - "AG NPP709 (Synatura®) has been demonstrated to be efficacious in decreasing cough and sputum in patients with acute upper respiratory infection and chronic inflammatory bronchitis. " 11/01/2013 - "1. Hederacoside C (HDC) is one of the active ingredients in Hedera helix leaf extract (Ivy Ex.) and AG NPP709, a new botanical drug to treat acute respiratory infection and chronic inflammatory bronchitis. "
5.	Bronchitis 05/01/2020 - "AG NPP709 (Synatura®) has been demonstrated to be efficacious in decreasing cough and sputum in patients with acute upper respiratory infection and chronic inflammatory bronchitis. " 11/01/2013 - "1. Hederacoside C (HDC) is one of the active ingredients in Hedera helix leaf extract (Ivy Ex.) and AG NPP709, a new botanical drug to treat acute respiratory infection and chronic inflammatory bronchitis. "

Related Drugs and Biologics

1.	Expectorants (Mucolytics)
2.	Fibrinogen (Factor I)
3.	Interleukin-6 (Interleukin 6)
4.	Interleukin-33
5.	hederacoside C